Want to see SE:ANNX full AI Analyst Report?
Annexin Pharmaceuticals AB (ANNX) Stock Statistics & Valuation Metrics
Total Valuation
Annexin Pharmaceuticals AB has a market cap or net worth of SEK 57.89M. The enterprise value is SEK 51.98M.
- Market Cap
- SEK 57.89M
- Enterprise Value
- SEK 51.98M
Share Statistics
Annexin Pharmaceuticals AB has 8,718,182 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 8,718,182
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Annexin Pharmaceuticals AB’s return on equity (ROE) is -1.48 and return on invested capital (ROIC) is -145.65%.
- Return on Equity (ROE)
- -1.48
- Return on Assets (ROA)
- -1.22
- Return on Invested Capital (ROIC)
- -145.65%
- Return on Capital Employed (ROCE)
- -1.46
- Revenue Per Employee
- 0
- Profits Per Employee
- -9.22M
- Employee Count
- 4
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Annexin Pharmaceuticals AB is -1.51. Annexin Pharmaceuticals AB’s PEG ratio is 0.03.
- PE Ratio
- -1.51
- PS Ratio
- 0.00
- PB Ratio
- 4.06
- Price to FCF
- -1.40
- Price to Operating Cash Flow
- -1.21
- PEG Ratio
- 0.03
Income Statement
In the last 12 months, Annexin Pharmaceuticals AB had revenue of 0 and earned -36.89M in profits. Earnings per share was -5.58.
- Revenue
- 0
- Gross Profit
- -48.00K
- Operating Income
- -36.31M
- Pretax Income
- -36.89M
- Net Income
- -36.89M
- EBITDA
- -36.84M
- Earnings Per Share (EPS)
- -5.58
Cash Flow
In the last 12 months, operating cash flow was -41.22M and capital expenditures 0, giving a free cash flow of -41.22M billion.
- Operating Cash Flow
- -41.22M
- Free Cash Flow
- -41.22M
- Free Cash Flow per Share
- -5.47
Dividends & Yields
Annexin Pharmaceuticals AB pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -71.21%
- Earnings Yield
- -84.15%
Stock Price Statistics
- Beta
- 0.83
- 52-Week Price Change
- -73.04%
- 50-Day Moving Average
- 10.34
- 200-Day Moving Average
- 12.93
- Relative Strength Index (RSI)
- 20.32
- Average Volume (3m)
- 9,322
Important Dates
Annexin Pharmaceuticals AB upcoming earnings date is Feb 11, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 22, 2026
- Next Earnings Date
- Feb 11, 2027
- Ex-Dividend Date
- ―
Financial Position
Annexin Pharmaceuticals AB as a current ratio of 5.47, with Debt / Equity ratio of 0.00%
- Current Ratio
- 5.47
- Quick Ratio
- 5.47
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.74
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Annexin Pharmaceuticals AB has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Annexin Pharmaceuticals AB EV to EBITDA ratio is -1.03, with an EV/FCF ratio of -1.05.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.03
- EV to Free Cash Flow
- -1.05
- EV to Operating Cash Flow
- -1.05
Balance Sheet
Annexin Pharmaceuticals AB has SEK 14.44M in cash and marketable securities with SEK 0.00 in debt, giving a net cash position of SEK 14.44M billion.
- Cash & Marketable Securities
- SEK 14.44M
- Total Debt
- SEK 0.00
- Net Cash
- SEK 14.44M
- Net Cash Per Share
- SEK 1.66
- Tangible Book Value Per Share
- SEK 1.63
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Annexin Pharmaceuticals AB is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 7.33%
Scores
- Smart Score
- ―
- AI Score
- 42
